Ligand Pharmaceuticals Incorporated Stock News

Ligand (LGND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shares, rose in value on Friday, 12/17/21, with the stock price up by 4.47% to the previous days close as strong demand from buyers drove the stock to $146.03. Actively observing the price movement in the last trading, the stock closed the session at $139.78, falling within a range of $138.06 What Analysts Were Expecting After Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) rose 4.47% Read More »

Equities research analysts expect that Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) will post sales of $62.70 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Ligand Pharmaceuticals earnings. The highest sales estimate is $65.45 million and the lowest is $59.94 million. Ligand Pharmaceuticals posted sales of $69.99 million in the []

Oregon Public Employees Retirement Fund grew its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) by 19.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,762 shares of the biotechnology companys stock after acquiring an additional 1,098 shares during the quarter. Oregon Public Employees Retirement []

Related Stocks: AMEH , SLQT , SGH , LPI , TALO , LGND , THS , INT , TRMK , CNK , ATGE , GME , SAIA , MSTR , SYKE , CORE , LMNX ,

Related Stocks: AMEH , SLQT , SGH , LPI , LGND , THS , INT , CNK , TRMK , ATGE , GME , SAIA , MSTR , SYKE , CORE , LMNX ,

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)s share price was up 2.7% during trading on Tuesday . The company traded as high as $159.92 and last traded at $159.46. Approximately 824 shares traded hands during trading, a decline of 99% from the average daily volume of 134,879 shares. The stock had previously closed at $155.24. A number of []

Equities analysts forecast that Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) will announce $62.70 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Ligand Pharmaceuticals earnings, with the lowest sales estimate coming in at $59.94 million and the highest estimate coming in at $65.45 million. Ligand Pharmaceuticals posted sales of $69.99 million []

Price T Rowe Associates Inc. MD reduced its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) by 8.6% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 9,366 shares of the biotechnology companys stock after selling 879 shares during the period. Price T Rowe Associates Inc. MDs holdings in Ligand Pharmaceuticals were worth $1,229,000 []

Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.

Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.

Prudential Financial Inc. decreased its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) by 52.8% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 11,957 shares of the biotechnology company’s stock after selling 13,397 shares during the period. Prudential Financial Inc.’s holdings in Ligand Pharmaceuticals were worth $1,569,000 as […]

Woodstock Corp lowered its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) by 0.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 68,666 shares of the biotechnology companys stock after selling 110 shares during the period. Woodstock Corp owned 0.41% []

Credit Suisse AG lowered its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) by 96.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,392 shares of the biotechnology companys stock after selling 702,236 shares during the period. Credit Suisse AGs holdings in Ligand []

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) COO Matthew W. Foehr sold 11,160 shares of the companys stock in a transaction on Thursday, November 11th. The shares were sold at an average price of $163.02, for a total transaction of $1,819,303.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible []